Entera Bio Stock Forecast, Price & News

-0.12 (-2.26 %)
(As of 07/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume85,506 shs
Average Volume5.30 million shs
Market Capitalization$123.00 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ENTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter.

Entera Bio logo

About Entera Bio

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.33 out of 5 stars

Medical Sector

1741st out of 4,434 stocks

Biological Products, Except Diagnostic Industry

253rd out of 422 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Entera Bio (NASDAQ:ENTX) Frequently Asked Questions

Is Entera Bio a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Entera Bio stock.
View analyst ratings for Entera Bio
or view top-rated stocks.

What stocks does MarketBeat like better than Entera Bio?

Wall Street analysts have given Entera Bio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Entera Bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Entera Bio?

Entera Bio saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 697,100 shares, an increase of 903.0% from the June 15th total of 69,500 shares. Based on an average daily trading volume, of 3,110,000 shares, the short-interest ratio is presently 0.2 days. Currently, 4.2% of the company's shares are short sold.
View Entera Bio's Short Interest

When is Entera Bio's next earnings date?

Entera Bio is scheduled to release its next quarterly earnings announcement on Thursday, August 19th 2021.
View our earnings forecast for Entera Bio

How were Entera Bio's earnings last quarter?

Entera Bio Ltd. (NASDAQ:ENTX) announced its earnings results on Wednesday, May, 19th. The company reported ($0.11) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $0.01. The firm earned $0.16 million during the quarter. Entera Bio had a negative net margin of 3,448.54% and a negative trailing twelve-month return on equity of 243.01%.
View Entera Bio's earnings history

How has Entera Bio's stock been impacted by Coronavirus?

Entera Bio's stock was trading at $2.78 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ENTX shares have increased by 86.7% and is now trading at $5.19.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ENTX?

3 equities research analysts have issued 12-month price objectives for Entera Bio's shares. Their forecasts range from $10.00 to $14.00. On average, they expect Entera Bio's share price to reach $12.00 in the next year. This suggests a possible upside of 131.2% from the stock's current price.
View analysts' price targets for Entera Bio
or view top-rated stocks among Wall Street analysts.

Who are Entera Bio's key executives?

Entera Bio's management team includes the following people:
  • Dr. Hillel Galitzer, Chief Operating Officer (Age 43, Pay $359k)
  • Dr. Phillip Schwartz Ph.D., Exec. VP, Pres of R&D and Director (Age 59, Pay $441k)
  • Dr. Arthur C. Santora II, M.D., Ph.D., Chief Medical Officer (Age 70, Pay $355k)
  • Dr. Spiros Jamas, CEO & Director (Age 60)
  • Ms. Dana Yaacov-Garbeli CPA, Chief Financial Officer (Age 32)
  • Dr. Roger J. Garceau, Chief Devel. Advisor & Director (Age 67)
  • Mr. Ramesh Ratan, U.S. Chief Financial Officer

Who are some of Entera Bio's key competitors?

What other stocks do shareholders of Entera Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include (CGC), Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA).

When did Entera Bio IPO?

(ENTX) raised $11 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00 per share. Maxim Group acted as the underwriter for the IPO and Joseph Gunnar was co-manager.

What is Entera Bio's stock symbol?

Entera Bio trades on the NASDAQ under the ticker symbol "ENTX."

How do I buy shares of Entera Bio?

Shares of ENTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Entera Bio's stock price today?

One share of ENTX stock can currently be purchased for approximately $5.19.

How much money does Entera Bio make?

Entera Bio has a market capitalization of $123.00 million and generates $370,000.00 in revenue each year. The company earns $-9,980,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does Entera Bio have?

Entera Bio employs 19 workers across the globe.

What is Entera Bio's official website?

The official website for Entera Bio is

Where are Entera Bio's headquarters?


How can I contact Entera Bio?

Entera Bio's mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The company can be reached via phone at 972-2532-7151 or via email at [email protected]

This page was last updated on 7/26/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.